1	Pandemic ST131 Escherichia coli presenting the UPEC/EAEC and ExPEC/EAEC
2	hybrid pathotypes recovered from extraintestinal infections in a clinical setting of the
3	Brazilian Amazon region
4	
5	Nathália M. S. Bighi ¹ , Érica L. Fonseca ^{1,*} , Fernanda S. Freitas ¹ , Sérgio M. Morgado ¹ and
6	Ana Carolina P. Vicente ¹
7	
8	¹ Laboratório de Genética Molecular de Microrganismos, Instituto Oswaldo Cruz, FIOCRUZ,
9	Rio de Janeiro, Brazil.
10	
11	Correspondence: Érica L. Fonseca, ericafon@ioc.fiocruz.br
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

26 Abstract

27 *Escherichia coli* is part of the commensal microbiota of human's and animal's gut. 28 However, they may become pathogenic due to the acquisition of virulence factors that 29 provide the ability to cause intestinal or extraintestinal infections, which makes E. coli the 30 main cause of diarrheagenic diseases and urinary tract infections (UTIs) worldwide, 31 respectively. Some strains, known as hybrids, may harbour a mix of virulence determinants 32 of both diarrheagenic (DEC) and extraintestinal E. coli (ExPEC) pathotypes. Reports of 33 hybrid *E. coli* in Brazil are rare, and the lineages associated with such pathotypes were poorly 34 explored. This study aimed to characterize E. coli strains recovered from extraintestinal 35 infections in a clinical setting of the Brazilian Amazon Region by means of lineage 36 determination, antibiotic resistance profile, and investigation of DEC and ExPEC virulence 37 markers. Fifteen ExPEC strains were recovered from distinct extraintestinal sites from 38 inpatients of the General Hospital of Roraima (GHR), placed in the Brazilian Amazon region. 39 Antibiotic susceptibility test revealed that all strains were multidrug-resistant and most of 40 them, including those recovered from urine, were resistant to fluoroquinolones, the main 41 therapeutic option for treating UTIs, probably due to the presence of Ser83Leu and 42 Asp87Asn substitutions in GyrA. The MLST analysis revealed the polyclonal nature of these 43 ExPEC strains since 11 STs were determined, including local and pandemic lineages, such as 44 ST69 and ST131. Among the 15 isolates, 12 were classified as hybrids, due to the presence of 45 the *aggR* virulence marker of the Enteroaggregative E. coli (EAEC) pathotype together with 46 at least one ExPEC (iutA, KPSMTII, sfaDE, papC, afaBC, iucD) or Uropathogenic E. coli 47 (UPEC) (vat, fuyA, chuA and yfcV) virulence determinants. These UPEC/EAEC (n=10) and 48 ExPEC/EAEC (n=2) hybrid strains were found among distinct lineages, including new STs, 49 and phylogroups (ST131/B2; ST1196/AxB1; ST9403/A; ST12394/A; NEW1-CC14/B2; 50 NEW2-CC155/B1; NEW3-CC155/B1; NEW4-CC131/B2) and, for the first time, a hybrid

51	phenotype was found in the pandemic ST131 lineage in Brazil. Therefore, this study provides
52	new information on the epidemiological scenario of hybrid E. coli strains, contributing to a
53	better understanding of the occurrence and pathogenic potential of these organisms.
54	
55	Keywords: HyPEC; ExPEC; ST69; ST131; virulence marker; pandemic lineage
56	

57 INTRODUCTION

58 Escherichia coli inhabits the intestinal tract of humans and other animals as an 59 important member of their microbiota [1]. However, the acquisition by horizontal gene 60 transfer of virulence determinants by certain E. coli clones has enabled them to cause not 61 only intestinal but also extraintestinal infections in different hosts. In this way, based on the 62 body site of infection, the host, and the presence of specific virulence markers, these bacteria 63 can be classified into diarrheagenic (DEC), mainly featured by the presence of specific 64 virulence factors directly related to diarrhoea, and extraintestinal pathogenic (ExPEC) E. coli, 65 defined primarily by their site of isolation [2]. The DEC group encompasses several 66 pathotypes, including enterotoxigenic (ETEC), enteropathogenic (EPEC), enteroinvasive 67 (EIEC), enteroaggregative (EAEC), and Shiga toxin-producing (STEC) E. coli. EPEC and 68 EAEC are considered the major pathotypes of diarrheagenic E. coli causing disease 69 worldwide, including in Brazil. These pathotypes carry genetic determinants involved with 70 disease development and can be used as molecular markers of the pathotype. 71 The ExPEC group includes the pathotypes neonatal meningitis-associated (NMEC), 72 human sepsis-associated (SEPEC), avian pathogenic (APEC), and uropathogenic (UPEC) E.

coli, which is the most prevalent pathotype among extraintestinal infections worldwide.

74 UPEC is particularly associated with urinary tract infections (UTIs) and is a leading cause of

75	both community-acquired and healthcare-associated UTIs. Currently, the most frequently
76	reported high-risk ExPEC lineages belonging to the MLST sequence type ST131, ST69,
77	ST10, ST405, ST38, ST95, ST648, ST73 and ST1193, which are known for their high
78	prevalence in extraintestinal infections worldwide and for their significant role in global
79	spread of multidrug resistance [3].
80	Studies <i>in vivo</i> revealed that the presence of at least two of five virulence genes (<i>pap</i> ,
81	afa/dra, sfa, kpsMTII, and iut/iuc) could be enough to cause extraintestinal infection in
82	immunocompetent individuals [4], and that E. coli co-harbouring of chuA, fyuA, vat, and yfcV
83	virulence genes were able to cause UTIs [5]. Additionally, due to horizontal gene transfer
84	events, organisms may emerge as hybrid strains capable of causing intestinal and
85	extraintestinal diseases due to the presence of virulence factors of both ExPEC and DEC
86	pathotypes [6].
87	Strains harbouring a blend of virulence markers of different pathotypes have been
88	described worldwide in both high-risk and local lineages, however, most of them correspond

to hetero-pathogenic strains (characterized by a combination of virulence markers from DEC pathotypes) [7-9]. A recent study in South Africa demonstrated the high prevalence of several different DEC hybrid pathotypes, including strains sharing three virulence markers of three different DEC pathotypes, which were recovered from inanimate surfaces and presented a higher resistance profile compared to the classic pathotypes identified [8]. Another report demonstrated the occurrence of different DEC hybrid strains recovered from healthy individuals in Mexico [9].

In Brazil, few studies have characterized and reported the occurrence of hybrid
strains in extraintestinal infection cases harbouring the combination of DEC and ExPEC or
UPEC virulence markers, such as UPEC/EAEC, UPEC/aEPEC, ExPEC/STEC,

99	ExPEC/aEPEC [10-18]. However, there is a lack of association concerning the STs of such
100	hybrid strains circulating in the country. Moreover, most of these reports on hybrid strains
101	were restricted to São Paulo, a cosmopolitan city of the Southeast Brazilian region, and until
102	now, all studies reporting E. coli infections in the Amazon Region were associated only with
103	diarrheagenic infections [19-22]. Therefore, further studies are required to investigate the
104	distribution and potential impact of these strains on the clinical outcomes of affected
105	individuals. For these reasons, the objective of this study was to characterize E. coli strains
106	recovered from extraintestinal infections in the Brazilian Amazon Region by means of
107	lineage determination (MLST), antibiotic resistance profile, and investigation of DEC and
108	ExPEC virulence markers.

109 METHODS

110 Clinical data, bacterial strains and antimicrobial susceptibility test

111	From December 2016 to February, 2018, 15 E. coli isolates were recovered from
112	extraintestinal infection cases at the General Hospital of Roraima (GHR), placed in Boa
113	Vista. The strains were isolated from blood (n=2), urine (n=7), catheter tip (n=1), vagina
114	secretion (n=1), leg secretion (n=1), soft tissue (n=1), and operative wound secretion (n=2).
115	Species identification was performed with the automated VITEK2, and confirmed by
116	sequencing the 16S rRNA and the MLST genes. These strains are part of the Bacterial
117	Culture Collection of the Laboratory of Molecular Genetics of Microrganisms, FIOCRUZ.

118 Antimicrobial Susceptibility testing

119	The antibiotic susceptibility profile was determined by disc-diffusion method
120	according to clinical and laboratory standards institute (CLSI) guidelines [23] For the
121	following antibiotics: gentamicin, amikacin, kanamycin, tobramycin, neomycin,
122	streptomycin, imipenem, meropenem, ertapenem, cephalothin, cefoxitin, cefuroxime,
123	ceftazidime, ceftriaxone, cefotaxime, cefepime, azithromycin, clarithromycin, erythromycin,
124	ampicillin, ampicillin/sulbactam, amoxicillin, amoxicillin/clavulanic acid, carbenicillin,
125	penicillin, aztreonam, piperacillin/tazobactam, ticarcillin/clavulanic acid, nalidixic acid,
126	ciprofloxacin, norfloxacin, levofloxacin, ofloxacin, colistin sulphate, sulphonamide,
127	trimethoprim, sulfamethoxazole/trimethoprim, chloramphenicol, fosfomycin, nitrofurantoin,
128	tetracycline and minocycline.

129 Genotyping by Multilocus sequence typing (MLST)

130	The genetic relationship among the ExPEC strains was established by MLST based
131	on the Achtman MLST scheme (adk, fumC, gyrB, icd, mdh, purA and recA)
132	(http://mlst.warwick.ac.uk). Clonal complexes (CCs) were considered when sequence types
133	(STs) shared five or more identical alleles taking into account the seven genes considered in
134	the MLST scheme.

135 Detection of resistance genes by polymerase chain reaction (PCR) and sequencing

- 136 The isolates were screened by PCR and sequencing for the presence of the genes
- 137 frequently associated with β -lactam resistance in *E. coli* such as
- 138 bla_{SHV} , bla_{GES} , bla_{TEM} , bla_{CTX-M} (class A β -lactamases). The plasmid-mediated
- 139 fluoroquinolone (FQ) resistance qnr genes and the presence of mutations in the quinolone
- 140 resistance-determining region (QRDR) of *gyrA* was also investigated (Table 1).

141 Molecular Characterization of Hybrid Strains

142	The presence of DEC and ExPEC virulence determinants was screened by PCR
143	(Table 1). Those strains presenting at least one of the DEC pathotypes virulence markers
144	were considered hybrid strains [13]. The DEC virulence factors screened were <i>eae</i> and $bfpB$
145	genes, associated with epithelial adhesion in EPEC; the $aggR$ gene, a universal regulator of
146	EAEC virulence involved with the aggregative adhesion fimbriae (AAF) production; the $stx1$
147	and stx2 genes, related to the Shiga toxins production in STEC; the estH, estP and elT,
148	involved with the production of heat-stable and heat-labile toxins in ETEC; the <i>invE</i> gene that
149	encodes a regulatory protein that controls the transcriptional of invasion genes in EIEC
150	pathotype; the vat, fuyA, chuA and yfcV, all markers of UPEC; and ExPEC markers iutA,
151	KPSMTII, sfaDE, papC, afaBC, iucD.
152 153	RESULTS AND DISCUSSION
154	The phenotypic analysis revealed that all <i>E. coli</i> ExPEC strains (n=15) were classified as
155	multidrug-resistant (MDR) according to resistance classification criteria [24] (Table 1).
156	Among the β -lactam antibiotics, all isolates were resistant to at least one of these antibiotics,
157	and such phenotype could be explained by the presence of the bla_{TEM} gene in 14/15 isolates.
158	In fact, <i>bla</i> _{TEM} is frequently associated with plasmids in <i>E. coli</i> , and it was the most prevalent
159	gene among ExPEC recovered from UTI cases in São Paulo, Brazil [25]. However, although
160	the <i>bla</i> _{CTX-M} has been frequently associated with ExPEC in Brazil and worldwide [26], this
161	gene was not found in our sample, as well as the other screened β -lactamase genes bla_{GES} and
162	$bla_{\rm SHV}$.
163	Moreover, a high prevalence of fluoroquinolone resistance was observed (73%)
164	among the ExPEC strains. Although none of them carried any qnr allele, all FQ-resistant
165	isolates presented mutations in the Quinolone Resistance-Determining Region (QRDR) of
166	gyrA that led to the amino acid substitution Ser83Leu and Asp87Asn, known to be involved

with FQ resistance emergence [27]. Interestingly, these substitutions were recently reported
as the determinants of FQ resistance in ExPEC strains recovered from UTI cases in São Paulo
[12].

170 The MLST analysis revealed a great diversity, in which 11 STs were assigned to the 171 15 ExPEC strains: ST69, ST131, ST8886, ST1196, ST9403, ST3180, ST12394, and four 172 different new sequence types belonging to CC155 (n=2), CC14 (n=1) and CC131 (n=1), 173 demonstrating the polyclonal nature of these hybrid strains. The most prevalent lineage 174 among our sample was ST131, a pandemic clonal complex of the B2 phylogroup often 175 associated with an arsenal of resistance and virulence genes, contributing to the success of 176 this clone in spreading through clinical settings worldwide. The ST69 is another pandemic 177 lineage belonging to the phylogroup D usually associated with clinics and food/environment 178 contamination in several countries [27]. As found here, Lara and Colleagues have 179 demonstrated the occurrence of ExPEC ST69 presenting the hybrid pathotype UPEC/EAEC 180 in Brazil [10]. However, in spite of ST131 prevalence in Brazil, this is the first report of this 181 lineage presenting a hybrid pathotype (UPEC/EAEC) in that country (Table 2). 182 Considering the *E. coli* virulome, 9/19 virulence factors characterizing DEC and 183 ExPEC pathotypes were found in the studied samples in different frequencies and 184 combinations (Table 2). The presence of at least one extraintestinal virulence marker was 185 observed in all isolates, corroborating the nature of the infection sites from which they were 186 recovered. The *iucD* gene, which is part of the operon involved with aerobactin siderophore 187 synthesis, was the most prevalent ExPEC marker among the isolates (12/15). This gene is 188 associated with iron uptake systems, facilitating its survival and pathogenicity and playing a 189 crucial role in the bacteria's ability to cause infections and evade the host's immune response. 190 Among the 15 ExPEC isolates analysed, 12 (80%) had at least one marker used to define ExPEC and DEC pathotypes, being characterized as hybrid strains. The three strains 191

classified as non-hybrids belonged to the pandemic lineages ST131/phylogroup B2 (EC44)
and ST69/phylogroup D (EC39) and to the local ST8886 (EC40). Only 13 entries in
Enterobase (<u>https://enterobase.warwick.ac.uk/species/index/ecoli</u>) have been found for
ST8886, and in most cases, they corresponded to strains recovered from environmental sites
in USA in 2015 and only one recovered from an animal source in Canada in 2022. Thus, this
study reported the first clinical case belonging to this lineage.

198 Concerning the hybrid strains, it was verified the presence of UPEC/EAEC (n=10) 199 and ExPEC/EAEC (n=2) (when UPEC markers were absent, or the strain had been recovered 200 from a different body site other than urine). The aggR gene, considered a diarrheagenic factor 201 that defines the EAEC pathotype, was found in all hybrid isolates, indicating that they would 202 have the ability to cause intestinal disorders despite presenting in extraintestinal infections. 203 EAEC is recognized as an important cause of diarrhoea worldwide and can be considered the 204 most common DEC pathotype in *E. coli* in Brazil. However, *E. coli* strains with a hybrid 205 enteroaggregative/uropathogenic (UPEC/EAEC) genotype have sporadically emerged as a 206 cause of extraintestinal infections in Brazil [10-18]. Here we demonstrated the high 207 prevalence of such hybrid pathotypes in distinct lineages causing infections in the Amazon 208 region.

Most of UPEC/EAEC hybrid strains belonged to the pandemic and widespread ST131 (one of them was assigned to a new ST of the CC131) (Table 2). They were recovered from distinct extraintestinal sites and presented a heterogeneous profile of virulence markers. The unique non-hybrid ST131 strain was the EC44, which was a UPEC recovered from UTI that presented both UPEC and ExPEC virulence markers. On the other hand, local STs (ST9403, ST3180 and ST12394) belonging to different phylogroups (A, B1 and B2) and recovered from distinct body sites, including blood, were also classified as UPEC/EAEC hybrid strains.

216	Interestingly, in spite of the diversity of infection sites, most of the ExPEC strains were
217	recovered from urine, and all but one were resistant to the tested fluoroquinolones (Table 2),
218	which are the first choice antibiotics for treating UTIs. These findings probably accounted for
219	treatment failure, compromising the success of clinical outcomes.
220	Interestingly, in spite of the UPEC/EAEC EC49 strain being a new local ST of
221	CC14/phylogroup B2, this isolate exhibited the highest number of ExPEC and UPEC
222	virulence markers, besides the EAEC marker $aggR$ (Table 2). This demonstrates that not only
223	pandemic high-risk clones display an enhanced pathogenicity and that emerging strains may
224	possess a high level of virulence fitness.
225	The other class of hybrids (ExPEC/EAEC) corresponded to strains (n=2) that
226	carried ExPEC virulence markers and the <i>aggR</i> EAEC marker. The strains belonged to a new
227	ST from CC155/phylogroup B1 (EC52) and to the local ST1196 belonging to phylogroup
228	AxB1 (EC47) (Table 2). A recent study in Mozambique demonstrated that a hybrid
229	ExPEC/EAEC strain recovered from blood belonged to the pandemic ST131 lineage and
230	presented a remarkable virulence profile [28]. These findings revealed that ExPEC/EAEC
231	hybrids are associated with distinct lineages. Interestingly, both ExPEC/EAEC strains
232	identified here were recovered from urine although no UPEC virulence marker had been
233	identified. This was also the case of the non-hybrid EC39 strain, belonging to the pandemic
234	ST69/phylogroup D, that had been characterized as a UPEC pathotype due to the site of
235	infection (urine), although all UPEC virulence markers were absent (Table 2). These
236	findings suggest that their ability to infect the urinary tract would be related to other
237	mechanisms that were not investigated in this study. In fact, UPEC employs various virulence
238	strategies, such as binding to urinary tract epithelial cells, iron acquisition, toxin production,
239	and evasion of the host's immune system. These virulence factors are commonly encoded by

240	genes found in	pathogenicity	<i>islands</i>	(PAIs),	which are	often 1	mobilized	through	horizontal
	0			· //				0	

- 241 gene transfer and could have been lost from those UPEC strains [14]. Furthermore, the
- 242 presence of UPEC factors in strains recovered from sites other than urine, such as the non-
- 243 hybrid EC40 strain (Table 2), demonstrates their ability to colonize and survive in the urinary
- tract, but also that other virulence determinants were involved in the establishment of
- 245 extraintestinal infections in those cases.

246 CONCLUSION

247 This study contributes to a better understanding of the occurrence and pathogenic

248 potential of hybrid strains of *E. coli*. Besides, the association of pathotype and lineage

- 249 definition provides new information in the scenario of the global epidemiology of ExPEC
- 250 hybrid strains.

251

252 Funding information

- 253 This work was supported by Oswaldo Cruz Institute grant, Fundação Coordenação de
- 254 Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de
- 255 Desenvolvimento Científico e Tecnológico (CNPq) and Fundação Carlos Chagas Filho de
- 256 Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Processo SEI-
- **257** 260003/019688/2022.
- 258

259 **Conflicts of interest**

260 The authors declare that there are no conflicts of interest.

261

262 Ethical statement

- 263 This study was approved by the Oswaldo Cruz Foundation Ethics Committee (CAAE:
- 264 39978114.5.0000.5248).

265

266 References

267	1.	Leimbach A, Hacker J, Dobrindt U. E. coli as an all-rounder: the thin line between
268		commensalism and pathogenicity. Curr Top Microbiol Immunol 2013;358:3-32.
269	2.	Sora VM, Meroni G, Martino PA, Soggiu A, Bonizzi L, et al. Extraintestinal
270		Pathogenic Escherichia coli: Virulence Factors and Antibiotic Resistance. Pathogens
271		2021;10:1355.
272	3.	Kocsis B, Gulyás D, Szabó D. Emergence and Dissemination of Extraintestinal
273		Pathogenic High-Risk International Clones of Escherichia coli. Life (Basel) 2022;
274		12:2077.
275	4.	Johnson JR, Murray AC, Gajewski A, Sullivan M, Snippes P, et al. Isolation and
276		molecular characterization of nalidixic acid-resistant extraintestinal pathogenic
277		Escherichia coli from retail chicken products. Antimicrob Agents Chemother
278		2003;47:2161-2168.
279	5.	Spurbeck RR, Dinh PC Jr, Walk ST, Stapleton AE, Hooton TM, et al.
280		Escherichia coli isolates that carry vat, fyuA, chuA, and yfcV efficiently colonize the
281		urinary tract. Infect Immun 2012;80:4115-4122.
282	6.	Braz S, Melchior K, Moreira CG. Escherichia coli as a Multifaceted Pathogenic and
283		Versatile Bacterium. Front Cell Infect Microbiol 2020;10:1–9.
284	7.	Lee W, Sung S, Ha J, Kim E, An ES, et al. Molecular and Genomic Analysis of the
285		Virulence Factors and Potential Transmission of Hybrid Enteropathogenic and
286		Enterotoxigenic Escherichia coli (EPEC/ETEC) Strains Isolated in South Korea. Int J
287		Mol Sci 2023;24:12729.

288	8.	Rakhalaru P, Munzhedzi L, Abia ALK, Kabue JP, Potgieter N, et al. Prevalence
289		and Antimicrobial Resistance Profile of Diarrheagenic Escherichia coli from Fomites
290		in Rural Households in South Africa. Antibiotics (Basel) 2023;12:1345.
291	9.	Méndez-Moreno E, Caporal-Hernandez L, Mendez-Pfeiffer PA, Enciso-
292		Martinez Y, López RR, et al. Characterization of Diarreaghenic Escherichia coli
293		Strains Isolated from Healthy Donors, including a Triple Hybrid Strain. Antibiotics
294		(Basel) 2022;11:833.
295	10	Lara FBM, Nery DR, Oliveira PM, Araujo ML, Carvalho FRQ, et al. Virulence
296		Markers and Phylogenetic Analysis of Escherichia coli Strains with Hybrid
297		EAEC/UPEC Genotypes Recovered from Sporadic Cases of Extraintestinal
298		Infections. Front Microbiol 2017;8:146.
299	11	. Schüroff PA, Abe CM, Silva JW, Coelho CP, Andrade FB, et al. Role of
300		aggregate-forming pilus (AFP) in adherence and colonization of both intestinal and
301		urinary tracts. Virulence 2022;13:1423-1433.
302	12	Nascimento JAS, Santos FF, Valiatti TB, Santos-Neto JF, Santos ACM, et al.
303		Frequency and Diversity of Hybrid Escherichia coli Strains Isolated from Urinary
304		Tract Infections. Microorganisms 2021;9:693.
305	13	Nascimento JAS, Santos FF, Santos-Neto JF, Trovão LO, Valiatti TB, et al.
306		Molecular Epidemiology and Presence of Hybrid Pathogenic Escherichia coli among
307		Isolates from Community-Acquired Urinary Tract Infection. Microorganisms 2022;
308		10:302.

309	14 Tanabe RHS	Dias RCB. Ors	si H. de Lira DRP.	. Vieira MA. <i>et al</i>	Characterization
000	1 1	\mathbf{D} ias $\mathbf{R} \mathbf{C} \mathbf{D}$, $\mathbf{O} \mathbf{C}$, ii, ut Lii a Dii i		

- 310 of Uropathogenic Escherichia coli Reveals Hybrid Isolates of Uropathogenic and
- 311 Diarrheagenic (UPEC/DEC) E. coli. *Microorganisms* 2022;10:645.
- 312 15. Furlan JPR, Ramos MS, Dos Santos LDR, Rosa RS, Stehling EG. Multidrug-
- resistant Shiga toxin-producing Escherichia coli and hybrid pathogenic strains of
- bovine origin. *Vet Res Commun* 2023; online ahead of print.
- 315 16. Munhoz DD, Richards AC, Santos FF, Mulvey MA, Piazza RMF. E. coli
- 316 Common pili promote the fitness and virulence of a hybrid aEPEC/ExPEC strain
- 317 within diverse host environments. *Gut Microbes* 2023;15:2190308.
- 318 17. de Lira DRP, Cavalcanti AMF, Pinheiro SRS, Orsi H, Dos Santos LF, et al.
- 319 Identification of a hybrid atypical enteropathogenic and enteroaggregative Escherichia
- 320 coli (aEPEC/EAEC) clone of serotype O3:H2 associated with a diarrheal outbreak in
- 321 Brazil. *Braz J Microbiol* 2021;52:2075-2079.
- 322 18. Valiatti TB, Santos FF, Santos ACM, Nascimento JAS, Silva RM, et al. Genetic
- 323 and Virulence Characteristics of a Hybrid Atypical Enteropathogenic and
- 324 Uropathogenic Escherichia coli (aEPEC/UPEC) Strain. *Front Cell Infect Microbiol*325 2020;10:492.
- 326 19. Vicente AC, Teixeira LF, Iniguez-Rojas L, Luna MG, Silva L, *et al.* Outbreaks of
 327 cholera-like diarrhoea caused by enterotoxigenic Escherichia coli in the Brazilian
 328 Amazon Rainforest. *Trans R Soc Trop Med Hyg* 2005;99:669-674.
- 329 20. Benevides-Matos N, Pieri FA, Penatti M, Orlandi PP. Adherence and virulence
 330 genes of Escherichia coli from children diarrhoea in the Brazilian Amazon. *Braz J*331 *Microbiol* 2015;46:131-137.

332	21. Taborda RLM, Silva LAD, Orlandi PP, Batista FS, Rodrigues RS, et al.
333	Characterization of enteroaggregative Escherichia coli among diarrheal children in
334	Western Brazilian Amazon. Arq Gastroenterol 2018;55:390-396.
335	22. Rodrigues RS, Lima NCDS, Taborda RLM, Esquerdo RP, Gama AR, et al.
336	Antibiotic resistance and biofilm formation in children with Enteropathogenic
337	Escherichia coli (EPEC) in Brazilian Amazon. J Infect Dev Ctries 2019;13:698-705.
338	23. Clinical and Laboratory Standards Institute. Performance Standards for
339	Antimicrobial Susceptibility Testing supplement M100. 32nd Ed. Wayne, PA: CLSI;
340	2021.
341	24. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al.
342	Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria an
343	international expert proposal for interim standard definitions for acquired resistance.
344	Clin Microbiol Infect 2012;18:268–281.
345	25. Santos-Neto JF, Santos ACM, Nascimento JAS, Trovão LO, Santos FF, et al.
346	Virulence Profile, Antibiotic Resistance, and Phylogenetic Relationships among
347	Escherichia coli Strains Isolated from the Feces and Urine of Hospitalized Patients.
348	Pathogens 2022;11:1528.
349	26. Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M β -lactamases:
350	temporal and geographical shifts in genotype. J Antimicrob Chemother 2017;
351	72:2145–2155.
352	27. Riley LW. Pandemic lineages of extraintestinal pathogenic Escherichia coli. Clin
353	Microbiol Infect 2014;20:380-390.
354	28. Santona A, Sumbana JJ, Fiamma M, Deligios M, Taviani E, et al. High-risk
355	lineages among extended-spectrum β -lactamase-producing Escherichia coli from

356	extraintestinal infections in Maputo Central Hospital, Mozambique. Int J Antimicrob
357	Agents 2022;60:106649.
358 359	
360	
361	
362	
363	
364	
365	
366	
367	
368	
369	
370	
371	
372	
373	
374	
375	
376	
377	
378	
379	
380	
381	

Primer name	Primer sequence (5' – 3')	Target
	Antibiotic resistance ge	nes
SHV F	TTCATGGCGTTACCTTTGAC	Class A β -lactamase <i>bla</i> _{SHV} genes
SHV R	CCGACAGAGTGCGGTATTTA	
GES F	ATGCGCTTCATTCACGCAC	ESBL Class A β -lactamase <i>bla</i> _{GES} genes
GES R	CTATTTGTCCGTGCTCAGGA	
TEM F	GTATCCGCTCATGAGACAATA	Class A β -lactamase <i>bla</i> _{TEM} genes
TEM R	TCTAAAGTATATATGAGTAAACTTGGTCTG	
CTX-M F	CGCTTTGCGATGTGCAG	ESBL Class A β -lactamase <i>bla</i> _{CTX-M} genes
CTX-M R	ACCGCGATATCGTTGGT	
QnrVC F	AAGTGAACTTCTCACATCAGG	Quinolone resistance <i>qnrVC</i> genes
QnrVC R	ATGATTACCCCTAATTGCTCC	
QnrA F	GATTTCTCACGCCAGGATTT	Quinolone resistance <i>qnrA</i> gene
QnrA R	TCKGAGCCCATCAAGGAAG	
QnrB F	GATCGWGAAAGYCAGAAAGG	Quinolone resistance <i>qnrB</i> gene
QnrB R	CCACARYTCRCAYTTTTC	
QnrC F	TGCAGACCTACGAGATGCTT	Quinolone resistance <i>qnrC</i> gene
QnrC R	TTCACGCCAGTTAAATCCAC	
QnrS F	ACGTGTTAACTTGCGTGAT	Quinolone resistance <i>qnrS</i> gene
QnrS R	GCAATTTTGATACCTGATG	
GyrA F	CGTTGGTGACGTAATCGGTA	ORDR of gyrA gene
GyrA R	GTGTTCCATCAGCCCTTCA	
	Virulence genes	
Eae F	GTGGCGAATACTGGCGAGACT	
Eae R	CGACGGTGAAAAGAATGGGG	EPEC virulence marker
BfpB F	CGATAAAACTGATACTGGGCAGC	
BfpB R	GTGCTTCCCGAACAGTCACT	
AggR F	CGATACATTAAGACGCCTAAAG	EAEC virulence marker
AggR R	TCTGATACATTAAATTCATCTGC	
Stx1 F	CAGTTAATGTGGTGGCGAAGG	
Stx1 R	CACCAGACAATGTAACCGCTG	STEC virulence marker
Stx2 F	ATCCTATTCCCGGGAGTTTACG	
Stx2 R	GCGTCATCGTATACACAGGAGC	
EstH F	GCTAAACCAGTAGAGTC	
EstH R	CACCCGGTACAAGCAGG	
EstP F	AGTCAGTCAACTGAATCAC	ETEC virulence marker
EstP R	ATTTTCTCAGCACCAATAC	
elT F	CACACGGAGCTCCTCAG	
elT R	CAAACTAGTTTTCCATACTG	
invE F	CGATAGATGGCGAGAAATTATATCCCG	EIEC virulence marker
invE R	CGATCAAGAATCCCTAACAGAAGAATCA	
Vat F	TCAGGACACGTTCAGGCATTCAGT	
Vat R	GGCCAGAACATTTGCTCCCTTGTT	
FyuA F	GTAAACAATCTTCCCGCTCGGCAT	
FyuA R	ΤĠĂĊĠĂŦŦĂĂĊĠĂĂĊĊĠĠĂĂĠĠĠĂ	LIPEC virulence marker
	IUACUAI IAACUAACCUUAAUUUA	
ChuA F	CTGAAACCATGACCGTTACG	
ChuA F ChuA R	CTGAAACCATGACCGTTACG TTGTAGTAACGCACTAAACC	

382 Table 1. Primers used in this study

yfcV R iutA F iutA R KpsMTII F KpsMTII R sfaDE F sfaDE R papC F papC R afaBC F afaBC R iucD F	GTAATCTGGAATGTGGTCAGG GGCTGGACATCATGGGAACTGG CGTCGGGAACGGGTAGAATCG GCGCATTTGCTGATACTGTTG CATCCAGACGATAAGCATGAGCA CTCCGGAGAACTGGGTGCATCTTAC CGGAGGAGTAATTACAAACCTGGCA GTGGCAGTATGAGTAATGACCGTTA ATATCCTTTCTGCAGGGATGCAATA GGCAGAGGGCCGGCAACAGGC CCCGTAACGCGCCAGCATCTC TCCTCATTTTCCTGGCATC	ExPEC virulence marker	
<u>1ucD R</u>	AGITIATTTCCGCCGCTTCT		
384			
385			
386			
387			
388			
389			
390			
391			
392			
393			
394			
395			
396			
397			
398			
399			
400			
401			

Fable 2. Clinical and genetic information of the hybrid *E. coli* strains in this study

Strain	Strain Infection site		CC	Phylogroup	Antibiotic resistance profile	Pat	hotype Genetic Ma	rkers	Hybrid Classification
						DEC	EXPEC	UPEC	
EC39	Urine	69	69	D	NEO, CEF, CLA, ERI, CB, AMP, PEN, SXT, SUL,	-	kpsMTII	-	-
					TMP				
EC40	Blood	8886	-	B2	NEO, CXM, AZI, CLA, ERI, AMP, PEN, SXT, SUL, TMP	-	-	fyuA, yfcV	-
					KAN, NEO, STR, CEF, FOX, CXM, CAZ, CRO,				
EC41	Leg	131	131	B2	CTX, FEP, AMP, AMX, CB, PEN, TIM, CLA, ERI,	aggR	iucD	fyuA, yfcV	UPEC/EAEC
	secretion				NAL, CIP, NOR, LEV, OFX, SXT, SUL, TMP, MIN				
					GEN, TOB, KAN, NEO, STR, CEF, FOX, CXM,				
EC42	Urine	131	131	B2	CAZ, CRO, CTX, FEP, AMP, SAM, AMX, AMC,	aggR	iucD	yfcV	UPEC/EAEC
					CB. PEN. TIM. ATM. CLA. ERI. NAL. CIP. NOR.				

LEV, OFX, SXT, SUL, TMP, MIN, TET

					NEO, STR, CEF, FOX, CXM, CAZ, CRO, CTX,				
EC43	Catheter tip	131	131	B2	FEP, AMP, AMX, CB, PEN, TIM, AZI, CLA, ERI,	aggR	iutA, kpsMTII, iucD	yfcV	UPEC/EAEC
					NAL, CIP, NOR, LEV, OFX, SXT, SUL, TMP, TET				
					GEN, TOB, KAN, NEO, CEF, FOX, CXM, CAZ,		iutA, kpsMTII,		
EC46	Soft tissue	NEW 4	131	B2	CRO, CTX, FEP, AMP, SAM, AMX, AMC, CB,	aggR	papC, iucD	fyuA, yfcV	UPEC/EAEC
					PEN, TIM, ATM, CLA, NAL, CIP, NOR, LEV, OFX				
EC47	Urine	1196	_	AxB1	KAN, NEO, CEF, AMP, CB, PEN, AZI, CLA, ERI,	aggR	iutA. afaBC	_	EXPEC/EAEC
2017	0	1170			NAL, CIP, NOR, LEV, OFX				2
EC48	Vagina	9403	-	А	KAN, NEO, STR, AMP, CB, PEN, AZI	aggR	iutA, kpsMTII,	fyuA, yfcV	UPEC/EAEC
	secretion						papC, iucD		
					GEN, TOB, KAN, NEO, STR, CEF, FOX, CXM,				
EC44	Urine	131	131	B2	CAZ, CRO, CTX, FEP, AMP, SAM, AMX, AMC,	-	iutA, kpsMTII,	fyuA, yfcV	-
					CB, PEN, TIM, ATM, AZI, CLA, ERI, NAL, CIP,		papC iucD		
					NOR, LEV, OFX, SXT, SUL, TMP, TET				
					TOB, KAN, NEO, STR, CEF, FOX, CXM, CAZ,				

EC45	Urine	131	131	B2	CRO, CTX, FEP, AMP, SAM, AMX, AMC, CB,	aggR	iutA, kpsMTII,	fyuA, yfcV	UPEC/EAEC
					PEN, TIM, TZP, ATM, AZI, CLA, ERI, NAL, CIP,		afaBC, iucD		
					NOR, LEV, OFX, SXT, SUL, TMP				
					KAN, NEO, STR, CEF, CTX, AMP, SAM, AMX,		iutA, kpsMTII,	vat, fyuA,	
EC49	Urine	NEW 1	14	B2	AMC, CB, PEN, TIM, AZI, CLA, ERI, NAL, CIP,	aggR	papC, afaBC, iucD	yfcV	UPEC/EAEC
					NOR, LEV, OFX, SXT, SUL, TMP				
7050		2100	14	Da	VANANES STRODO AND DEN AZU SUA	D		C 11	
EC20	-	3180	14	B 2	KAN, NEO, STR, CRO, AMP, PEN, AZI, CLA,	aggR	iutA, kpsM111, iucD	yfc V	UPEC/EAEC
					ERI, NAL, CIP, NOR, LEV, OFX, CHL				
					KAN, NEO, STR, CEF, CRO, AMP, SAM, AMX,				
EC51	Blood	NEW 2	155	B1	CB, PEN, TIM, CLA, ERI, SXT, SUL, TMP, MIN,	aggR	iutA, iucD	fyuA	UPEC/EAEC
					TET				
EC52	Urine	NEW 3	155	B1	AMP, PEN, CLA, NAL, CIP, NOR, LEV, OFX, MIN	aggR	iutA, afaBC, iucD	-	EXPEC/EAEC
					AMK, GEN, TOB, KAN, NEO, STR, CEF, FOX,				
EC53	wound	12394	46	А	CXM, CAZ, CRO, CTX, FEP, AMP, SAM, AMX,	aggR	iutA, iucD	fyuA	UPEC/EAEC
	secretion				CB, PEN, TIM, ATM, AZI, CLA, ERI, NAL, CIP,				
					NOR, LEV, OFX, TMP, MIN, TET				

Abbreviations: AMK, amikacin; GEN, gentamicin; TOB, tobramycin; KAN, kanamycin; NEO, neomycin; STR, streptomycin; CEF, cephalothin; FOX, cefoxitin; CXM, cefuroxime; CAZ, ceftazidime; CRO, ceftriaxone; CTX, cefotaxime; FEP, cefepime; AMP, ampicillin; SAM, ampicillin/sulbactam; AMX, amoxicillin; AMC, amoxicillin/clavulanate; CB, carbenicillin; PEN, penicillin; TIM, ticarcillin/clavulanate; TZP, piperacillin/tazobactam; ATM, aztreonam; AZI, azithromycin; CLA, clarithromycin; ERI, erythromycin; NAL, nalidixic acid; CIP, ciprofloxacin; NOR, norfloxacin; LEV, levofloxacin; OFX, ofloxacin; SXT, trimethoprim/sulfamethoxazole; SUL, sulphonamide; TMP, trimethoprim; MIN, minocycline; tetracycline; CHL, chloramphenicol.

ExPEC strains presenting hybrid pathotypes in the Amazon region

